Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human PDGFD Anticorps:
anti-Rat (Rattus) PDGFD Anticorps:
anti-Mouse (Murine) PDGFD Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal PDGFD Primary Antibody pour IP, WB - ABIN529260
Rizvi, Mertens, Bronk, Hirsova, Dai, Roberts, Kaufmann, Gores: Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. dans The Journal of biological chemistry 2014
Human Polyclonal PDGFD Primary Antibody pour IF (p), IHC (p) - ABIN714581
Hurley, Adams, Wang, Jiang, Meo Burt, Du, Xiao: Accelerated Fracture Healing in Transgenic Mice Overexpressing an Anabolic Isoform of Fibroblast Growth Factor 2. dans Journal of cellular biochemistry 2015
PDGF-D promotes tumor growth and aggressiveness of colorectal carcinoma. Down-regulation of PDGF-D inactivates Notch1 (Montrer NOTCH1 Anticorps)/Twist1 (Montrer TWIST1 Anticorps) axis, which could reverse epithelial mesenchymal transformation and prevent CRC (Montrer CALR Anticorps) progression.
significant correlations between DNA methylation (Montrer HELLS Anticorps) of the PDGFD gene promoter and the risk of developing either IA or BAVM
This study suggested that epithelial-mesenchymal transition process can be triggered by the PDGF-D/PDGFRb (Montrer PDGFRB Anticorps) axis in tongue squamous cell carcinoma, and then involved in the tumor cell invasion via activation of p38 (Montrer CRK Anticorps)/AKT (Montrer AKT1 Anticorps)/ERK (Montrer EPHB2 Anticorps)/ epithelial-mesenchymal transition pathway.
No specific genotype of rs974819 of Platelet-derived growth factor D demonstrated increased cardiovascular mortality in the total population, however, the male group with genotypes A/A and G/A demonstrated an increased risk that persisted in a multivariate evaluation where adjustments were made for well-known cardiovascular risk factors.
There are four platelet-derived growth factor (PDGF (Montrer PDGFA Anticorps)) genes (PDGFA (Montrer PDGFA Anticorps), PDGFB (Montrer PDGFB Anticorps), PDGFC (Montrer PDGFC Anticorps) and PDGFD) that reside on chromosomes 7, 22, 4 and 11.
polymorphism of rs7950273 in the PDGFD gene is not associated with ischaemic stroke in the Chinese Han population
Novel findings reveal a new paradigm in matriptase (Montrer ST14 Anticorps) activation involving PDGF-D-specific signal transduction leading to extracellular acidosis.
PDGF-D expression is associated with miR (Montrer MLXIP Anticorps)-106a and Twist1 (Montrer TWIST1 Anticorps) in HCC (Montrer FAM126A Anticorps) patients
PDGF-D is highly expressed by ASCs, where it acts as a potent mitogenic factor.
PDGFD, CDH1 and SLIT2 are upregulated in low grade meningiomas and schwannomas compared with healthy tissue.
Inactivation of the Pdgfd gene resulted in a mild phenotype in C57BL/6 mice, and the offspring was viable, fertile and generally in good health.
PDGF-D intensifies fibrogenesis by interfering with the fibrolytic activity of the TIMP-1 (Montrer TIMP1 Anticorps)/MMP-2 (Montrer MMP2 Anticorps)/MMP (Montrer MMP2 Anticorps)-9 (Montrer MMP9 Anticorps) system, and PDGF-D signaling is mediated through both PDGF (Montrer PDGFA Anticorps)-alpha and -beta receptors.
Radial glia require PDGFD-PDGFRbeta signalling in human but not mouse neocortex
PDGF D represents a potentially promising target for prostate carcinoma treatment resistance in the absence of PTEN function, and warrants further laboratory evaluation and clinical study.
Data indicate that the proteolytic processing of full-length PDGF-D is required for PDGF-D activation of preosteoclasts, and that beta-PDGFR (Montrer PDGFRB Anticorps) is present in activated osteoclasts.
identified PDGF (Montrer PDGFA Anticorps)-DD as an important target gene for antiangiogenic therapy due to its pleiotropic effects on vascular and non-vascular cells. PDGF (Montrer PDGFA Anticorps)-DD inhibition may offer new therapeutic options to treat neovascular diseases
Failure of laminin alpha4-mediated down-regulation of PDGF (Montrer PDGFA Anticorps) activity contributes to the progressive renal lesions in this animal model.
These results suggest that PDGF-D induce cellular transformation and promote tumour growth by accelerating the proliferation rate of the tumour cells, and by stimulation of tumour neovascularization.
PDGF-D plays an important role in the pathogenesis of tubulointerstitial injury through binding of PDGF (Montrer PDGFA Anticorps)-Rbeta in obstructive ureteral nephropathy
PDGF (Montrer PDGFA Anticorps)-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patterns.
The protein encoded by this gene is a member of the platelet-derived growth factor family. The four members of this family are mitogenic factors for cells of mesenchymal origin and are characterized by a core motif of eight cysteines, seven of which are found in this factor. This gene product only forms homodimers and, therefore, does not dimerize with the other three family members. It differs from alpha and beta members of this family in having an unusual N-terminal domain, the CUB domain. Two splice variants have been identified for this gene.
, iris-expressed growth factor
, platelet-derived growth factor D
, spinal cord derived growth factor B
, spinal cord-derived growth factor B
, spinal cord-derived growth factor-B
, platelet-derived growth factor, D polypeptide
, spinal-cord derived growth factor-B protein
, platelet derived growth factor D
, platelet-derived growth factor D-like